Article Text

Download PDFPDF
Presumed retinal pericapillary astrocytic hamartoma: multimodal imaging findings of a novel hamartomatous lesion
  1. Gerardo Ledesma-Gil1,
  2. Juliet Essilfie1,
  3. Alex Onishi2,
  4. Kenneth J Wald3,
  5. Yale L Fisher1,
  6. Amani A Fawzi2,
  7. Carol L Shields4,
  8. K Bailey Freund1,
  9. Jay Chhablani5
  1. 1Vitreous Retina Macula Consultants of New York, New York, New York, USA
  2. 2Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
  3. 3Ophthalmology, New York University School of Medicine, New York, New York, USA
  4. 4Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA
  5. 5UPMC Eye Center, Pittsburgh, Pennsylvania, USA
  1. Correspondence to Jay Chhablani, UPMC Eye Center, 203 Lothrop Street Pittsburgh 15213 PA, USA; jay.chhablani{at}gmail.com

Abstract

Purpose To describe the multimodal imaging findings of retinal lesions that clinically resemble retinal astrocytic hamartomas (RAHs), but also have unique characteristics that we believe represent a novel variant.

Methods Observational study. Five eyes in five patients with solitary retinal lesion evaluated at the retina division of three institutions. We describe the multimodal imaging findings including fundus photography, fundus autofluorescence, fluorescein angiography, spectral-domain optical coherence tomography (OCT), swept-source OCT, swept-source OCT angiography and ultrasonography.

Results The retinal lesions described shared similar appearance to RAHs but demonstrated unique features such as glistening granular appearance on fundus photographs with perivascular hyperreflectivity with OCT and OCT angiography.

Conclusion The lesions described herein appear to have unique characteristics that warrant a designation as a novel RAH variant. The name presumed retinal pericapillary astrocytic hamartoma is suggested.

  • Imaging
  • Retina
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests KBF is a consultant to Genentech, Allergan, Optovue, Zeiss, Bayer, Heidelberg Engineering and Novartis. He receives research funding from Genentech/Roche. JC is a consultant for Allergan, Novartis and OD-OS. The remaining authors have no relevant disclosures.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.